Zai Lab (ZLAB) and NovoCure (NVCR) said Monday that their phase 3 trial evaluating TTFields along with gemcitabine and nab-paclitaxel as a treatment for unresectable, locally advanced pancreatic adenocarcinoma achieved its primary endpoint, demonstrating a "statistically significant" improvement in median overall survival.
NovoCure (NVCR) plans regulatory filings in the US, EU, Japan, and other major markets, while Zai Lab plans to file for regulatory approval in China, the companies said
Novocure shares rose by more than 25% in premarket trading, while Zai Lab was up about 2%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。